Anti-angiogenesis effect on glioma of attenuated Salmonella typhimurium vaccine strain with flk-1 gene.
To investigate the anti-vasculature effects and the anti-glioma effects of attenuated Salmonella typhimurium vaccine strain expressing VEGFR2 (flk-1) gene, plasmid pcDNA3.1-flk1 was constructed and electro-transfected into live attenuated Salmonella typhimurium strain SL7207. Mouse models of intracranial G1261 glioblastoma were treated with an orally administered attenuated Salmonella typhimurium expressing flk-1 gene. The survival period was recorded and vessel density was observed by immunofluorescence. CTLs activity was measured by MTT assay. Our results showed that attenuated Salmonella typhimurium vaccine strain expressing flk-1 gene could significantly inhibit glioblastoma growth, reduce vessel density, prolong the survival period and improve the survival rate in these mice. The flk-1 specific CTLs activity was increased obviously after the vaccination. Our study showed that attenuated Salmonella typhimurium vaccine strain expressing flk-1 gene could break peripheral immune tolerance a in glioma gainst this self-antigen and kill endothelial cells by the orally administered vaccine and can be used for both prophylactic and therapeutic purposes.
Feng
Keke
K
Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and technology, Wuhan 430022, China.
Zhao
Hongyang
H
Chen
Jian
J
Yao
Dongxiao
D
Jiang
Xiaobing
X
Zhou
Wei
W
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D001932:Brain Neoplasms / Q000098:blood supply / Q000628:therapy*; D005260:Female; D005910:Glioma / Q000098:blood supply / Q000628:therapy*; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic; D022562:Salmonella Vaccines / Q000276:immunology / Q000494:pharmacology*; D012486:Salmonella typhimurium / Q000276:immunology*; D014170:Transformation, Genetic; D014613:Vaccines, Attenuated / Q000235:genetics / Q000276:immunology / Q000494:pharmacology; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000235:genetics* / Q000276:immunology
D020533:Angiogenesis Inhibitors; D022562:Salmonella Vaccines; D014613:Vaccines, Attenuated; D040301:Vascular Endothelial Growth Factor Receptor-2